Europe Ablation Technologies Market Size

Europe Ablation Technologies Market Analysis

The Europe Ablation Technologies Market is expected to register a CAGR of nearly 5.2 % during the forecast period.

The COVID-19 pandemic affected healthcare systems and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks. Moreover, catheter ablation procedures for atrial fibrillation (AF) were significantly curtailed during the peak of the COVID-19 pandemic to conserve healthcare resources and limit exposure. For instance, according to the study published by the National Library of Medicine, in January 2022, there were no cases of ablation-related COVID-19 transmission in the study population. As a result, fewer ablation procedures were performed, thereby negatively impacting the market. Thus, such circumstances greatly affected the market's growth rate throughout the initial pandemic phase. However, as the COVID-19 cases started to decline, the market started to show normal pre-pandemic level growth and is likely to continue its significant growth rate during the forecast period.

The factors propelling the studied market growth are the emergence of next-generation ablation products and technology and the growing burden of target diseases. For instance, an article published by the National Library of Medicine in June 2021 mentioned that the reported prevalence of cardiovascular diseases among patients with type 2 diabetes ranged from 6.9% to 40.8%. The prevalence of coronary heart disease ranged from 4.7 to 37%, stroke from 3.5 to 19.6%, peripheral artery disease from 2.5 to 13.0%, and heart failure from 4.3 to 20.1%. The high incidence of target diseases increases the demand for treatment, which, in turn, drives the market. Furthermore, the data published by the European Heart network in 2021 reported that in the European Union, more than 60 million people live with cardiovascular disease, and nearly 13 million new cases of cardiovascular diseases are diagnosed yearly. Such increasing prevalence of cardiovascular diseases, which led to an increasing need for treatment, is expected to drive the growth of the ablation technologies market.

Additionally, strategic initiatives such as product launches, mergers, acquisitions, partnerships, and others will lead to lucrative market growth. For instance, in January 2021, CardioFocus, Inc. expanded its existing French distribution partnership agreement with MicroPort CRM in France to include both Spain and Portugal to launch of HeartLight X3 ablation system. The HeartLight X3 ablation system is a complement to the MicroPort EP range of catheters and the Columbus 3D imaging system. Such development is expected to drive the growth of the market over the forecast period.

Therefore, owing to the factors above, the studied market is expected to grow significantly during the study period. However, stringent regulatory scenarios and the high cost of devices are expected to hinder the market's growth during the forecast period.